Meyers

Bristol Myers Squibb (BMS) is a premier global biopharmaceutical company dedicated to the discovery, development, and delivery of innovative medicines for serious diseases. The company holds a leading position in oncology, hematology, immunology, cardiovascular, and neuroscience, with a portfolio that includes blockbuster therapies such as Opdivo, Eliquis, and Revlimid. BMS has strategically expanded its pipeline through high-profile acquisitions, including Celgene, Karuna Therapeutics, and RayzeBio, positioning itself at the forefront of advanced modalities like targeted protein degradation and cell therapy. The company is currently navigating a significant portfolio transition, focusing on its 'New Product Portfolio' to drive long-term growth as older assets face generic competition. With a robust R&D engine and a commitment to digital transformation, BMS continues to advance a diverse pipeline of over 45 assets to address significant unmet medical needs globally.